The chemopreventive role of ursodeoxycholic acid in azoxymethane-treated rats: Suppressive effects on enhanced group II phospholipase A2 expression in colonic tissue

Cancer Letters

Volumn 134, Issue 2, 1998, Pages 129-139

  Ikegami, Tadashi ^a   Matsuzaki, Yasushi ^a   Shoda, Junichi ^a   Kano, Masahito ^a   Hirabayashi, Norio ^b   Tanaka, Naomi ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b Tokyo Tanabe Company Limited   (Japan)

Author keywords

Azoxymethane treated rats; Chemoprevention; Ursodeoxycholic acid

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; AZOXYMETHANE; MESSENGER RNA; PHOSPHOLIPASE A2; PROSTAGLANDIN E2; PROTEIN; URSODEOXYCHOLIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARACHIDONIC ACID METABOLISM; ARTICLE; CHEMOPROPHYLAXIS; COLON CARCINOGENESIS; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

ANIMALS; ANTICARCINOGENIC AGENTS; AZOXYMETHANE; CARCINOGENS; COLONIC NEOPLASMS; DNA PRIMERS; GASTROINTESTINAL AGENTS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; IMMUNOBLOTTING; MALE; PHOSPHOLIPASES A; PRECANCEROUS CONDITIONS; PROSTAGLANDINS; RANDOM ALLOCATION; RATS; RATS, INBRED F344; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIME FACTORS; URSODEOXYCHOLIC ACID;

EID: 0032418162     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(98)00248-1     Document Type: Article

References (49)

1. Willett W. Epidemiologic studies of diet and cancer. Med. Oncol. Tumor Pharmacother. 7:1990;93-97.
2. Wynder E., Reddy B., Weisburger J. Environmental dietary factors in colorectal cancer. Cancer. 70:(Suppl.):1991;1222-1228.
3. 2. Gut. 35:1994;675-678.
4. Marnett L. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res. 52:1992;5575-5589.
5. Thun M., Namboodiri M., Heath C.W. Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med. 325:1991;1593-1596.
6. 2 in bile acid caused promotion of colon carcinogenesis and anti-promotion by the cyclooxygenase inhibitor indomethacin. Jpn. J. Cancer Res. 78:1987;791-798.
7. Eberhart C., Coffey R., Radhika A., Giardiello F., Ferrenbach S., Dubois R. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 107:1994;1183-1188.
8. Kargman S., Charleson S., Cartwright M., Frank J., Rindeau D., Mancini J., Evans J., O'Neill G. Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey and human gastrointestinal tracts. Gastroenterology. 111:1996;445-454.
9. Sano H., Kawahito Y., Wilder R., Hashiramoto A., Mukai S., Asai K., Kimura S., Kato H., Kondo M., Hla T. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res. 55:1995;3785-3789.
10. 2 and diacylglycerol lipase are increased in human colorectal cancer. Br. J. Surg. 82:1995;475-478.
11. 2, phosphatidylinositol-specific phospholipase C activities and cyclooxygenase metabolite formation during different stages of colon tumor promotion in male F344 rats. Cancer Res. 56:1996;532-537.
12. Earnest D., Holubec H., Wali R., Jolley C., Bissonette M., Bhattacharyya A., Roy H., Khare S., Brasitus T. Chemoprevention of azoxymethane-induced colonic carcinogenesis by supplemental dietary ursodeoxycholic acid. Cancer Res. 54:1994;5071-5074.
13. Earnest D., Batta A., Holubec H., Jolley C., Brasitus T., Salen G. Chemoprevention of colon cancer by ursodeoxycholic acid: a possible mechanism of action. Gastroenterology. 108:1995;A463.
14. Rigas B., Tsioulias G., Allan C., Wali R., Brasitus T. The effects of bile acid and piroxicam on MHC antigen expression in rat colonocytes during colon cancer development. Immunology. 83:1994;319-323.
15. Brasitus T. Primary chemopreventive strategies for colorectal cancer: ursodeoxycholic acid and other agents. Gastroenterology. 109:1995;2036-2038.
16. Bird R. Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. Cancer Lett. 37:1987;147-151.
17. 2. J. Lipid Res. 34:1993;837-844.
18. 2. J. Biol. Chem. 263:1988;5724-5731.
19. 2 from rat spleen. J. Biol. Chem. 263:1988;5732-5738.
20. 2. Biochem. Biophys. Res. Commun. 162:1989;1030-1036.
21. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:1987;156-159.
22. 2 and the increased gene expression in the dentate gyrus following transient forebrain ischemia. Mol. Brain Res. 27:1994;335.
23. Feng L., Sun W., Xia Y., Tang W., Chanumugam P., Soyoola E., Wilson C., Hwang D. Cloning two isoforms of rat cyclooxygenase: differential regulation of their expression. Arch. Biochem. Biophys. 307:1993;361-368.
24. Magnuson B., Carr I., Bird R. Ability of aberrant crypt foci characteristics to predict colonic tumor incidence in rats fed cholic acid. Cancer Res. 53:1993;4499-4504.
25. Pretlow T., O'Riordan M., Kolman M., Jurcisek J. Colonic aberrant crypts in azoxymethane-treated F344 rats have decreased hexosaminidase activity. Am. J. Physiol. 136:1990;13-16.
26. Pretlow T., O'Riordan M., Somich G., Amini S., Pretlow T. Aberrant crypts correlate with tumor incidence in F344 rats treated with azoxymethane and phytate. Carcinogenesis. 13:1992;1509-1512.
27. 2 and cyclooxygenase, in the large bowel mucosa and neoplasms of F344 rates treated with naturally occurring carcinogen, 1-hydroxyanthraquinone. Cancer Lett. 97:1995;75-82.
28. Williams C., Luongo C., Redhika A., Zhang T., Lamps L., Nanney L., Beauchamp R., Dubois R. Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology. 111:1996;1134-1140.
29. 2. J. Biol. Chem. 269:1994;13057-13060.
30. Murakami M. Type II secretory phospholipase A2 associated with cell surfaces via C-terminal heparin binding lysine residues augments stimulus-initiated delayed prostaglandin generation. J. Biol. Chem. 271:1996;30041-30051.
31. 2. J. Biol. Chem. 264:1989;5768-5775.
32. 2. Biochim. Biophys. Acta. 117:1993;217-231.
33. 2 gene expression on human hepatoma cells by mediators of the acute phase response. J. Biol. Chem. 266:1991;2647-2651.
34. 2 immunochemically related to group II enzyme in inflammatory bowel disease: its correlation with disease activity of Crohn's disease and ulcerative colitis. Gut. 33:1992;914-921.
35. 2 in colonic mucosa of patients with Crohn's disease and ulcerative colitis. Gut. 35:1994;1593-1598.
36. 2 gene expression and activity in histologically normal ileal mucosa and in Crohn's ileitis. Gut. 37:1995;380-385.
37. 2 and demonstration of postoperative elevation. Enzyme. 45:1991;200-208.
38. 2 levels in patients with advanced cancer. Clin. Chim. Acta. 228:1994;91-99.
39. 2. FEBS Lett. 294:1991;247-251.
40. 2 added exogenously. J. Biochem. 110:1991;163-165.
41. 2 synthesis in human umbilical vein endothelial cells. J. Biol. Chem. 268:1993;839-844.
42. 2 generates the novel lipid mediator lysophosphatidic acid in membrane microvesicles shed from activated cells. Cell. 80:1995;919-927.
43. 2 gene is a candidate for the Mom1 locus, a major modifier of APCmin-induced intestinal neoplasia. Cell. 81:1995;957-966.
44. 2 gene alterations in human colorectal cancer. Cancer Res. 55:1995;5184-5186.
45. Tischfield J. A reassessment of the low molecular weight phospholipase A2 gene family in mammals. J. Biol. Chem. 272:1997;17247-17250.
46. 2 production by blocking mRNA synthesis and post-transcriptional expression. J. Biol. Chem. 265:1990;12745-12748.
47. Tanaka H., Makino I. Ursodeoxycholic acid-dependent activation of the glucocorticoid receptor. Biochem. Biophys. Res. Commun. 188:1992;942-948.
48. Tanaka H., Makino Y., Miura T., Hirano F., Okamoto K., Komura K., Sato Y., Makino I. Ligand-independent activation of the glucocorticoid receptor by ursodeoxycholic acid. J. Immunol. 156:1996;1601-1608.
49. Roy H., Bissonnette M., Frawley B.P., Wali R., Niedziela S., Earnest D., Brasitus T. Selective preservation of protein kinase C-ζ in the chemoprevention of azoxymethane-induced colonic tumors by piroxicam. FEBS Lett. 336:1995;143-145.